Charles Bonnet Syndrome: Successful treatment of visual hallucinations due to vision loss with selective serotonin reuptake inhibitors

被引:30
|
作者
Lang, Undine E.
Stogowski, Dariusz
Schuze, Doreen
Domula, Markus
Schmidt, Eckart
Gallinat, Jueergen
Tugtekin, Sems Malte
Felber, Werner
机构
[1] Univ Dresden, Dept Psychiat, D-01099 Dresden, Germany
[2] Univ Dresden, Dept Ophthalmol, Dresden, Germany
[3] Heart Ctr Dresden, Dept Cardiac Surg, Dresden, Germany
关键词
serotonin; Charles Bonnet Syndrome; CBS; hallucinations; epileptic; SSRI; venlafaxine; escitalopram;
D O I
10.1177/0269881106075275
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Visual hallucinations are a common and often distressing consequence of vision toss, particularly in age-related macular degeneration. Charles Bonnet Syndrome (CBS) is defined by the triad of complex visual hallucinations, ocular pathology causing visual deterioration and preserved cognitive status. So far, although this condition is frequent, no established treatment for CBS has been stated. We report here the case of a 78-year-old woman, who came in our hospital because of a 4-week tong mild depressive symptomatology. For 1 year she experienced daily sudden, unexpected, vivid and elaborate hallucinations. Insight was completely present, so the patient stated that the hallucinations were unreal and that the faces, geometrical figures and animals she saw every day were possibly due to her vision loss. The Mini Mental State Examination, digit span and verbal fluency were administered and no cognitive impairment was reported. The visual acuity was hand motion. After 4 days of treatment with venlafaxine the hallucinations completely disappeared. This is the first case to show that selective serotonin (and noradrenalin) reuptake inhibitors may be an effective and well-tolerated treatment for visual hallucinations associated with vision Loss, and it adds to evidence implicating serotonergic pathways in the pathogenesis of visual hallucinations.
引用
收藏
页码:553 / 555
页数:3
相关论文
共 50 条
  • [31] Lesion network guided neuromodulation to the extrastriate visual cortex in Charles Bonnet syndrome reduces visual hallucinations: A case study
    Raymond, Nicolas
    Trotti, Rebekah
    Oss, Emma
    Lizano, Paulo
    CORTEX, 2024, 178 : 245 - 248
  • [32] Emergence of kleptomania during treatment for depression with serotonin selective reuptake inhibitors
    Kindler, S
    Dannon, PN
    Iancu, I
    Sasson, Y
    Zohar, J
    CLINICAL NEUROPHARMACOLOGY, 1997, 20 (02) : 126 - 129
  • [33] Brain serotonin transporter availability predicts treatment response to selective serotonin reuptake inhibitors
    Kugaya, A
    Sanacora, G
    Staley, JK
    Malison, RT
    Bozkurt, A
    Khan, S
    Anand, A
    van Dyck, CH
    Baldwin, RM
    Seibyl, JP
    Charney, D
    Innis, RB
    BIOLOGICAL PSYCHIATRY, 2004, 56 (07) : 497 - 502
  • [34] Acute neural effects of selective serotonin reuptake inhibitors versus noradrenaline reuptake inhibitors on emotion processing: Implications for differential treatment efficacy
    Outhred, Tim
    Hawkshead, Brittany E.
    Wager, Tor D.
    Das, Pritha
    Malhi, Gin S.
    Kemp, Andrew H.
    NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS, 2013, 37 (08) : 1786 - 1800
  • [35] Charles Bonnet Syndrome in Patients with Open-Angle Glaucoma Prevalence and Correlation to Visual Field Loss
    Peters, Dorothea
    Molander, Stellan
    Lomo, Trine
    Singh, Amardeep
    OPHTHALMOLOGY GLAUCOMA, 2022, 5 (03): : 337 - 344
  • [36] Neonatal withdrawal syndrome after in utero exposure to selective serotonin reuptake inhibitors
    Nordeng, H
    Lindemann, R
    Perminov, KV
    Reikvam, Å
    ACTA PAEDIATRICA, 2001, 90 (03) : 288 - 291
  • [37] Running wheel activity is sensitive to acute treatment with selective inhibitors for either serotonin or norepinephrine reuptake
    Weber, Martin
    Talmon, Sonja
    Schulze, Ilka
    Boeddinghaus, Christine
    Gross, Gerhard
    Schoemaker, Hans
    Wicke, Karsten M.
    PSYCHOPHARMACOLOGY, 2009, 203 (04) : 753 - 762
  • [38] Running wheel activity is sensitive to acute treatment with selective inhibitors for either serotonin or norepinephrine reuptake
    Martin Weber
    Sonja Talmon
    Ilka Schulze
    Christine Boeddinghaus
    Gerhard Gross
    Hans Schoemaker
    Karsten M. Wicke
    Psychopharmacology, 2009, 203 : 753 - 762
  • [39] ROLE OF SELECTIVE SEROTONIN REUPTAKE INHIBITORS ON THE TREATMENT OF CHRONIC AND/OR RESISTANT MAJOR DEPRESSION
    AGUGLIA, E
    DEVANNA, M
    DIGRAZA, MF
    GIORNALE DI NEUROPSICOFARMACOLOGIA, 1995, 17 (03): : 73 - 77
  • [40] Maternal Psychiatric Conditions, Treatment With Selective Serotonin Reuptake Inhibitors, and Neurodevelopmental Disorders
    Ames, Jennifer L.
    Ladd-Acosta, Christine
    Fallin, M. Daniele
    Qian, Yinge
    Schieve, Laura A.
    DiGuiseppi, Carolyn
    Lee, Li-Ching
    Kasten, Eric P.
    Zhou, Guoli
    Pinto-Martin, Jennifer
    Howerton, Ellen M.
    Eaton, Christopher L.
    Croen, Lisa A.
    BIOLOGICAL PSYCHIATRY, 2021, 90 (04) : 253 - 262